keyword
MENU ▼
Read by QxMD icon Read
search

Antipsychotics

keyword
https://www.readbyqxmd.com/read/28742396/valbenazine-for-tardive-dyskinesia
#1
Oliver Freudenreich, Gary Remington
Tardive dyskinesia (TD) remains a clinical concern for any patient who receives an antipsychotic. While the overall risk of developing TD is lower with newer antipsychotics compared to older agents, a significant number of patients who require long-term treatment will develop TD. Recently, valbenazine (brand name Ingrezza) became the first drug to be approved by the FDA specifically for the treatment of TD. In this New Drug Review, we summarize the basic pharmacology and clinical trial results for valbenazine...
2017: Clinical Schizophrenia & related Psychoses
https://www.readbyqxmd.com/read/28742291/evaluating-the-effect-of-the-changes-in-fda-guidelines-for-clozapine-monitoring
#2
Ryan S Sultan, Mark Olfson, Christoph U Correll, Erica J Duncan
BACKGROUND: Concerns exist that clozapine is underutilized in the management of treatment-resistant schizophrenia. Although a 2015 change in the US Food and Drug Administration (FDA) monitoring recommendations lowered the threshold of the absolute neutrophil count for treatment interruption from 1,500/μL to 1,000/μL and removed white blood cell count thresholds from the monitoring algorithm, the implications of this policy change on clozapine interruptions remain unknown. METHODS: We analyzed outpatient prescribing records for antipsychotic medications in the Veterans Integrated Service Network 7 (VISN 7) database between 1999 and 2012 to assess the potential impact of the recent changes in FDA neutropenia monitoring recommendations on clozapine treatment discontinuation...
July 18, 2017: Journal of Clinical Psychiatry
https://www.readbyqxmd.com/read/28742260/incorporating-patient-preferences-into-estimation-of-optimal-individualized-treatment-rules
#3
Emily L Butler, Eric B Laber, Sonia M Davis, Michael R Kosorok
Precision medicine seeks to provide treatment only if, when, to whom, and at the dose it is needed. Thus, precision medicine is a vehicle by which healthcare can be made both more effective and efficient. Individualized treatment rules operationalize precision medicine as a map from current patient information to a recommended treatment. An optimal individualized treatment rule is defined as maximizing the mean of a pre-specified scalar outcome. However, in settings with multiple outcomes, choosing a scalar composite outcome by which to define optimality is difficult...
July 25, 2017: Biometrics
https://www.readbyqxmd.com/read/28741647/the-association-between-season-of-birth-age-at-onset-and-clozapine-use-in-schizophrenia
#4
J S Kim, C M Park, J A Choi, E Park, H J Tchoe, M Choi, J K Suh, Y H Kim, S H Won, Y C Chung, K Y Bae, S K Lee, S C Park, S H Lee
OBJECTIVE: This study aimed to determine whether the rate of clozapine use, an indicator of refractoriness in schizophrenia, is associated with the season of birth and age at onset in patients with schizophrenia based on nationwide data. METHODS: Patients with schizophrenia (n = 114 749) who received prescriptions for antipsychotic medication between 2008 and 2014 were retrospectively identified from the Korean National Health Insurance Service database. The study population was divided into three groups based on their age at the onset of schizophrenia (early, middle, and late onset)...
July 25, 2017: Acta Psychiatrica Scandinavica
https://www.readbyqxmd.com/read/28741387/baseline-characteristics-and-treatment-patterns-of-patients-with-schizophrenia-initiated-on-once-every-three-month-paliperidone-palmitate-in-the-real-world-setting
#5
Kruti Joshi, Marie-Hélène Lafeuille, Brianne Brown, Willy Wynant, Bruno Emond, Patrick Lefebvre, Neeta Tandon
OBJECTIVES: Since May 2015, adult patients with schizophrenia adequately treated with once-monthly paliperidone palmitate (PP1M) may be transitioned to once-every-three-month paliperidone palmitate (PP3M). This study aims to describe baseline characteristics and treatment patterns of patients with schizophrenia initiated on PP3M in the real-world setting. METHODS: Pharmacy and medical claims from 05/2014-09/2016 for adult patients with schizophrenia initiated on PP3M (index date) in the Symphony Health Solutions database were analyzed...
July 25, 2017: Current Medical Research and Opinion
https://www.readbyqxmd.com/read/28741044/efficacy-and-tolerability-of-asenapine-compared-with-olanzapine-in-borderline-personality-disorder-an-open-label-randomized-controlled-trial
#6
Paola Bozzatello, Paola Rocca, Maria Uscinska, Silvio Bellino
BACKGROUND: Asenapine is a new second-generation antipsychotic that is understudied in borderline personality disorder (BPD). Only one study investigating the use of the drug in this indication (an open-label pilot study) has been conducted to date. OBJECTIVE: The present open-label, randomized, controlled trial aimed to evaluate the efficacy and tolerability of asenapine in comparison with olanzapine, the most broadly studied antipsychotic in BPD. METHODS: A total of 51 outpatients aged between 18 and 50 years with a diagnosis of BPD based on Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) criteria were assigned for 12 weeks to asenapine (5-10 mg/day) or olanzapine (5-10 mg/day)...
July 24, 2017: CNS Drugs
https://www.readbyqxmd.com/read/28740828/omega-3-fatty-acids-related-to-cognitive-impairment-in-patients-with-schizophrenia
#7
Kazumi Satogami, Shun Takahashi, Shinichi Yamada, Satoshi Ukai, Kazuhiro Shinosaki
Cognitive impairment is strongly associated with functional outcome in patients with schizophrenia but its pathophysiology remains largely unclear. Involvement of omega-3 fatty acids in the cognitive function of healthy individuals and patients with neuropsychiatric disease has received increasing attention. The aim of this study was to examine the relationship between omega-3 fatty acids with cognitive function, social function, and psychiatric symptoms in patients with schizophrenia. The subjects included 30 patients with schizophrenia or schizoaffective disorder...
September 2017: Schizophrenia Research. Cognition
https://www.readbyqxmd.com/read/28740637/antipsychotic-induced-hyperprolactinemia-in-tourette-syndrome
#8
REVIEW
Judith J G Rath, Marlies E J Deen, Hessel van Houten, Sebastiaan F T M de Bruijn, Joop van Gerven, Dick Mul
For many years, Tourette syndrome (TS) was considered to be a rare disorder, but tics and TS are now recognized as fairly common childhood-onset conditions. Children and adolescents with TS are frequently treated with antipsychotics, either as monotherapy or in combination with psychostimulants, melatonin and selective serotonin reuptake inhibitors (SSRIs). Antipsychotics are most often used in schizophrenia and related psychotic disorders, and in these conditions hyperprolactinemia is one of the most common adverse effects associated with antipsychotics, occurring in 40-50% of patients...
July 2017: Therapeutic Advances in Psychopharmacology
https://www.readbyqxmd.com/read/28740470/manual-dexterity-in-schizophrenia-a-neglected-clinical-marker
#9
Maxime Térémetz, Loïc Carment, Lindsay Brénugat-Herne, Marta Croca, Jean-Pierre Bleton, Marie-Odile Krebs, Marc A Maier, Isabelle Amado, Påvel G Lindberg
Impaired manual dexterity is commonly observed in schizophrenia. However, a quantitative description of key sensorimotor components contributing to impaired dexterity is lacking. Whether the key components of dexterity are differentially affected and how they relate to clinical characteristics also remains unclear. We quantified the degree of dexterity in 35 stabilized patients with schizophrenia and in 20 age-matched control subjects using four visuomotor tasks: (i) force tracking to quantify visuomotor precision, (ii) sequential finger tapping to measure motor sequence recall, (iii) single-finger tapping to assess temporal regularity, and (iv) multi-finger tapping to measure independence of finger movements...
2017: Frontiers in Psychiatry
https://www.readbyqxmd.com/read/28739492/efficacy-and-safety-of-citalopram-compared-to-atypical-antipsychotics-on-agitation-in-nursing-home-residents-with-alzheimer-dementia
#10
Giovanni Viscogliosi, Iulia Maria Chiriac, Evaristo Ettorre
OBJECTIVE: To assess efficacy and safety of citalopram compared to quetiapine and olanzapine for the treatment of agitation in patients with Alzheimer disease (AD). DESIGN: Longitudinal, 6-month study. SETTING: Nursing home (NH). PARTICIPANTS: 75 NH residents with AD and agitation, randomized to citalopram (n = 25), quetiapine (n = 25), or olanzapine (n = 25). MEASUREMENTS: Changes in Neuropsychiatric Inventory (NPI) agitation subscale score and the modified Alzheimer Disease Cooperative Study-Clinical Global Impression of Change (mADCS-CGIC) were used to assess treatment efficacy...
July 21, 2017: Journal of the American Medical Directors Association
https://www.readbyqxmd.com/read/28739149/oral-medication-for-agitation-of-psychiatric-origin-a-scoping-review-of-randomized-controlled-trials
#11
Samuel Mullinax, Farhad Shokraneh, Michael P Wilson, Clive E Adams
BACKGROUND: Understanding more about the efficacy and safety of oral second-generation antipsychotic medications in reducing the symptoms of acute agitation could improve the treatment of psychiatric emergencies. OBJECTIVE: The objective of this scoping review was to examine the evidence base underlying expert consensus panel recommendations for the use of oral second-generation antipsychotics to treat acute agitation in mentally ill patients. METHODS: The Cochrane Schizophrenia Group's Study-Based Register was searched for randomized controlled trials comparing oral second-generation antipsychotics, benzodiazepines, or first-generation antipsychotics with or without adjunctive benzodiazepines, irrespective of route of administration of the drug being compared...
July 21, 2017: Journal of Emergency Medicine
https://www.readbyqxmd.com/read/28738347/negative-beliefs-about-voices-in-patients-with-borderline-personality-disorder-are-associated-with-distress-a-plea-for-cognitive-behavioural-therapy
#12
Christina W Slotema, Jan Dirk Blom, Mathijs Deen, Marieke B A Niemantsverdriet, Mark van der Gaag, Hans W Hoek, Iris E C Sommer
BACKGROUND: Auditory verbal hallucinations (AVH) are experienced by 21-54% of patients diagnosed with a borderline personality disorder (BPD), and ensuing distress is often high. Little is known about the beliefs these patients foster about their voices, and the influence thereof on distress and need for hospitalisation. METHODS: In a convenience sample of 38 BPD outpatients with AVH, data were collected with the aid of the Psychotic Symptom Rating Scales (PSYRATS), Beliefs about Voices Questionnaire (BAVQ), Social Comparison Rating Scale (SCRS), and Voice Power Differential Scale (VPDS)...
July 22, 2017: Psychopathology
https://www.readbyqxmd.com/read/28738259/reasons-associated-with-treatment-non-adherence-in-schizophrenia-in-a-pakistan-cohort
#13
Irshad Ahmad, Muhammad Tahir Khalily, Brian Hallahan
non-adherence in patients with schizophrenia is the most common reason for a relapse of psychosis. In a cohort of participants in Pakistan who suffered a relapse of psychosis, we aimed to identify the principal factors associated with non-adherence, including any culture specific factors that might not be as significant in other jurisdictions. Semi-structured interviews were undertaken at four psychiatric hospitals in the Peshawar region in Pakistan with 55 participants (44 male and 11 female) diagnosed with schizophrenia, who had suffered a relapse of psychosis subsequent to treatment non-adherence...
July 13, 2017: Asian Journal of Psychiatry
https://www.readbyqxmd.com/read/28738100/multiple-neurotoxic-effects-of-haloperidol-resulting-in-neuronal-death
#14
Henry A Nasrallah, Alexander T Chen
BACKGROUND: Several published studies have reported an association between antipsychotic medications, especially first-generation agents, and a decline in gray matter volume. This prompted us to review the possible neurotoxic mechanisms of first-generation antipsychotics (FGAs), especially haloperidol, which has been widely used over the past several decades. METHODS: A PubMed search was conducted using the keywords haloperidol, antipsychotic, neurotoxicity, apoptosis, oxidative stress, and neuroplasticity...
August 1, 2017: Annals of Clinical Psychiatry: Official Journal of the American Academy of Clinical Psychiatrists
https://www.readbyqxmd.com/read/28737445/preclinical-pharmacokinetics-and-biodistribution-studies-of-asenapine-maleate-using-novel-and-sensitive-rp-hplc-method
#15
Renuka S Managuli, Karthik Gourishetti, Rekha R Shenoy, Kunnatur B Koteshwara, Meka Sreenivasa Reddy, Srinivas Mutalik
AIM: Asenapine maleate (ASPM) is a newer antipsychotic drug available as a sublingual tablet in the market. EXPERIMENTAL: To investigate the pharmacokinetic and tissue distribution study of ASPM following oral administration in rats, reversed-phase HPLC method was developed and validated. RESULTS: ASPM was extracted from plasma and tissue matrix by liquid-liquid extraction technique and analyzed using mobile phase consisted of phosphate buffer pH 3...
July 24, 2017: Bioanalysis
https://www.readbyqxmd.com/read/28737428/chromatographic-determination-of-zonisamide-topiramate-and-sulpiride-in-plasma-by-a-fluorescent-turn-on-chemosensor
#16
Fawzia A Ibrahim, Amira F El-Yazbi, Mira M Wagih, Magda A Barary
AIM: Antiepileptics (AEDs) and antipsychotics are often coprescribed. Interactions between these drugs may affect both efficacy and toxicity. Therefore, drug monitoring is necessary for appropriate dosage adjustments. MATERIALS & METHODS: Specific 'turn-on' chemosensor, 4-chloro-7-nitrobenzofurazan is used for selective and sensitive determination of two AEDs: zonisamide (ZON) and topiramate (TOP) with the antipsychotic sulpiride (SUL) in epileptic patients' plasma followed by reversed-phase-HPLC separation without any interference...
July 24, 2017: Bioanalysis
https://www.readbyqxmd.com/read/28736102/antipsychotic-drugs-for-the-acute-treatment-of-patients-with-a-first-episode-of-schizophrenia-a-systematic-review-with-pairwise-and-network-meta-analyses
#17
Yikang Zhu, Marc Krause, Maximilian Huhn, Philipp Rothe, Johannes Schneider-Thoma, Anna Chaimani, Chunbo Li, John M Davis, Stefan Leucht
BACKGROUND: The first episode of schizophrenia is a pivotal phase of this debilitating illness. Which drug to use remains controversial without a summary of all direct or indirect comparisons of drugs. We did a systematic review with pairwise and network meta-analyses of efficacy and tolerability. METHODS: We searched MEDLINE, Embase, PsycINFO, Cochrane Library, PubMed, Biosis, and ClinicalTrials.gov for randomised controlled trials of antipsychotics for the acute treatment of first-episode schizophrenia, published up to Nov 17, 2016...
July 20, 2017: Lancet Psychiatry
https://www.readbyqxmd.com/read/28736101/choice-of-antipsychotic-to-treat-first-episode-schizophrenia
#18
David Taylor
No abstract text is available yet for this article.
July 20, 2017: Lancet Psychiatry
https://www.readbyqxmd.com/read/28735693/concomitant-use-of-atypical-antipsychotics-with-other-psychotropic-medication-classes-and-the-risk-of-type-2-diabetes-mellitus
#19
Mehmet Burcu, Julie M Zito, Daniel J Safer, Laurence S Magder, Susan dosReis, Fadia T Shaya, Geoffrey L Rosenthal
OBJECTIVE: More than half of youth treated with atypical antipsychotic (AAP) medications are also treated with concomitant antidepressants or stimulants. This study assessed the association between antidepressant or stimulant use concomitant with AAPs and the risk of incident type 2 diabetes mellitus (T2DM). METHOD: Medicaid Analytic eXtract data were used to conduct a retrospective cohort study of youth (aged 5-20 years) who initiated AAP treatment. In AAP-treated youth, concomitant antidepressant (selective serotonin reuptake inhibitors [SSRI]/serotonin-norepinephrine reuptake inhibitors [SNRIs], tricyclic/other cyclic antidepressants [TCAs], and other antidepressants) or stimulant use was assessed...
August 2017: Journal of the American Academy of Child and Adolescent Psychiatry
https://www.readbyqxmd.com/read/28735690/polypharmacy-in-youth-treated-with-antipsychotics-do-antidepressants-or-stimulants-add-to-the-risk-for-type-2-diabetes
#20
EDITORIAL
Christoph U Correll, Britta Galling
No abstract text is available yet for this article.
August 2017: Journal of the American Academy of Child and Adolescent Psychiatry
keyword
keyword
3580
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"